CG Oncology (NASDAQ:CGON) Lowered to Strong Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of CG Oncology (NASDAQ:CGON) from a sell rating to a strong sell rating in a research report released on Saturday.

Several other equities research analysts have also commented on CGON. Piper Sandler boosted their target price on shares of CG Oncology from $82.00 to $85.00 and gave the stock an “overweight” rating in a research report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a report on Friday, July 17th. Truist Financial raised their price objective on shares of CG Oncology from $82.00 to $85.00 and gave the company a “buy” rating in a research note on Friday. Wedbush boosted their price objective on shares of CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Finally, HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of CG Oncology in a research report on Wednesday, July 29th. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $83.18.

CG Oncology Trading Up 0.3%

Shares of CGON stock opened at $75.10 on Friday. The stock has a 50 day simple moving average of $67.12 and a 200-day simple moving average of $63.95. The company has a market cap of $6.62 billion, a price-to-earnings ratio of -27.92 and a beta of 0.23. CG Oncology has a 12-month low of $23.65 and a 12-month high of $77.00.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.24). CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 26.58%. The business had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $0.36 million. On average, equities analysts forecast that CG Oncology will post -3.03 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other CG Oncology news, Director Leonard E. Post sold 5,000 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $70.00, for a total value of $350,000.00. Following the sale, the director owned 5,000 shares of the company’s stock, valued at approximately $350,000. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Brian Guan-Chyun Liu purchased 371,085 shares of the company’s stock in a transaction dated Thursday, June 25th. The stock was purchased at an average price of $66.87 per share, with a total value of $24,814,453.95. Following the transaction, the director owned 1,886,236 shares of the company’s stock, valued at approximately $126,132,601.32. This represents a 24.49% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have sold 37,129 shares of company stock worth $2,663,817. 4.80% of the stock is owned by corporate insiders.

Institutional Trading of CG Oncology

Hedge funds have recently bought and sold shares of the company. Whittier Trust Co. of Nevada Inc. purchased a new stake in shares of CG Oncology in the fourth quarter valued at $27,000. NFSG Corp acquired a new stake in shares of CG Oncology during the 1st quarter worth $34,000. Comerica Bank raised its position in shares of CG Oncology by 100.4% in the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after buying an additional 515 shares during the period. Fifth Third Bancorp purchased a new position in shares of CG Oncology in the 1st quarter worth about $74,000. Finally, KBC Group NV acquired a new position in CG Oncology during the first quarter valued at approximately $78,000. Institutional investors and hedge funds own 26.56% of the company’s stock.

Key Stories Impacting CG Oncology

Here are the key news stories impacting CG Oncology this week:

• Positive Sentiment: Analysts raised price targets: Piper Sandler increased its target from $82 to $85 and assigned an “overweight” rating, implying approximately 13.2% upside. Benzinga
• Positive Sentiment: Truist Financial also raised its target from $82 to $85 and upgraded its view to “buy,” citing a more constructive outlook for CG Oncology. The Fly
• Positive Sentiment: HC Wainwright maintained a “buy” rating and a $100 target. The firm modestly increased its long-term FY2030 EPS forecast to $6.88 from $6.77, reinforcing expectations for significant future earnings growth as the company advances its pipeline. MarketBeat
• Positive Sentiment: CG Oncology reported second-quarter revenue of $1.16 million, substantially above the $0.36 million consensus estimate, while also highlighting pipeline and business progress. CG Oncology Second-Quarter Results
• Neutral Sentiment: Royal Bank of Canada lowered its target from $81 to $79 but retained an “outperform” rating. The reduced target still represents roughly 5.2% potential upside and may reflect valuation calibration rather than a fundamental downgrade. Ticker Report
• Negative Sentiment: CG Oncology reported a quarterly loss of $0.90 per share, wider than the $0.66 consensus loss and the $0.54 loss recorded a year earlier. The earnings shortfall could limit gains despite strong analyst targets. Zacks Q2 Earnings Report
• Negative Sentiment: HC Wainwright reduced its FY2029 EPS estimate from $2.43 to $2.34, signaling some moderation in its intermediate-term earnings outlook, although its buy rating and $100 target remain unchanged.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.